Monopar Therapeutics Inc. announced on June 3, 2025, that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index. This inclusion will be effective after the close of U.S. equity markets on June 27, 2025.
The Russell 2000® Index tracks the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000® Index. Inclusion in these indexes means Monopar will also be automatically included in relevant growth and value style indexes.
Quan Vu, Monopar’s Chief Financial Officer, stated that this is an important milestone reflecting the company's significant transformation and growth over the past year. This achievement is largely attributed to the growing recognition of their late-stage ALXN1840 drug candidate for Wilson disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.